Natera Inc SEC Filings

An officer of Natera, Inc. who serves as President, Clinical Diagnostics reported multiple equity transactions in December 2025. On 12/12/2025, the officer made a charitable gift of 180 common shares, exercised 8,876 and 13,500 stock options at an exercise price of $9.59 per share, and sold 4,692 shares at an average price of $230.7575 to cover the option exercise price and tax obligations. On 12/15/2025, the officer made an additional charitable gift of 115 shares. After these transactions, the officer directly owns 126,450 common shares and holds 5,125 stock options at $9.59 per share, which are fully exercisable and expire on 04/07/2026.

Natera, Inc. reported insider activity by a company director involving both equity awards and stock sales. On 10/31/2025, the director received 132 Restricted Stock Units (RSUs) in lieu of a $23,750 quarterly cash retainer for board service, and these RSUs were fully vested at issuance, with each RSU representing one share of common stock.

Following this grant, the director held 68,761 common shares directly. On 12/12/2025, the director sold several blocks of Natera common stock: 14,372 shares at a weighted average price of $226.6174, 21,910 shares at $227.3532, 11,987 shares at $228.4858, and 150 shares at $229.095, all in multiple trades within narrow price ranges. After these transactions, the director directly owned 20,342 Natera shares.

Natera, Inc. reported an insider transaction by an officer serving as its SEC. and Chief Legal Officer. On December 4, 2025, this officer exercised stock options to acquire 6,902 shares of Natera common stock at an exercise price of $19.68 per share, converting derivative securities into common stock.

Following the transaction, the officer directly beneficially owned 208,601 shares of Natera common stock. The filing also shows 5,598 remaining stock options with a $19.68 exercise price, expiring on March 21, 2029, and notes that the option shares are fully exercisable.

Natera, Inc. (NTRA) reported insider selling by a director on a Form 4. On November 24, 2025, estate planning vehicles associated with the reporting person sold multiple blocks of Natera common stock, each reported as open-market sales. The trades used weighted average prices, with individual transactions occurring in ranges from $228.70 to $239.07 per share.

After the reported sales, the director indirectly beneficially owned 1,154,198 shares of Natera common stock through estate planning vehicles. One footnote states this indirect position includes 4,411 shares transferred to an estate planning vehicle in a transaction exempt from Section 16. The pricing details are available in ranges, and the reporting person has undertaken to provide exact breakdowns of shares sold at each price upon request.

Natera, Inc. (NTRA) director and co‑founder reported open‑market sales of company stock. On 11/20/2025, the reporting person sold 10,000 shares of Natera common stock at a weighted average price of $225.0816 per share under a Rule 10b5‑1 trading plan adopted on December 11, 2024, and continued to hold 222,660 shares directly afterward.

On 11/21/2025, 2,000 shares were sold at a weighted average price of $230.0097 per share through the Caraluna 1 Trust and 2,000 shares were sold at a weighted average price of $230.0055 per share through the Caraluna 2 Trust, both under a separate Rule 10b5‑1 trading plan adopted on June 7, 2024, leaving 23,282 shares held in each trust. The shares in the trusts are held for the benefit of the trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.

Natera, Inc. director reports option exercises and share sales. A Natera director filed a Form 4 showing multiple transactions in Natera common stock on November 19 and 20, 2025. The director exercised stock options to acquire 5,112 shares at an exercise price of $40.93 on November 19, and then exercised options for 600 shares at $40.93 and 7,068 shares at $41.19 on November 20. On the same dates, the director sold several blocks of Natera common stock in open market transactions at weighted average prices ranging from about $213.18 to $224.92 per share, under a Rule 10b5-1 trading plan adopted on August 20, 2025. Following these transactions, the director reported owning 18,359 shares of Natera common stock directly and no remaining options in the reported option grants.

Natera (NTRA) director and co‑founder reported open‑market sales of common stock under Rule 10b5‑1 plans. On 11/07/2025, multiple sales were executed at weighted average prices between $190.00 and $198.38, leaving 232,660 shares held directly after the transactions. On 11/11/2025, additional sales by the Caraluna 1 Trust and Caraluna 2 Trust occurred at weighted averages between $206.68 and $209.29; following these, each trust showed 25,282 shares. The reporting person disclaims beneficial ownership of the trust‑held shares.

Natera, Inc. reported strong Q3 2025 topline growth alongside wider losses. Total revenues reached $592.2 million, up from $439.8 million a year ago, driven mainly by product revenues of $590.2 million. The company posted a net loss of $87.5 million, compared with a $31.6 million loss in Q3 2024, and a basic and diluted loss per share of $0.64 versus $0.26.

Operating expenses increased as Natera continued investing in its platform: research and development was $173.4 million and selling, general and administrative was $308.5 million. Revenue in the quarter included a $55.1 million net increase from changes in estimates for tests delivered in prior periods that were fully collected, which reduced loss per share by $0.40, and a $2.9 million revenue reduction from estimated insurance refunds, which increased loss per share by $0.02.

Liquidity remained solid. Cash, cash equivalents and restricted cash were $1.04 billion at September 30, 2025. Year‑to‑date operating cash flow was $141.4 million. The balance sheet shows $80.3 million outstanding on the Credit Line and $1.25 billion in stockholders’ equity. As context, common shares outstanding were 138,014,465 as of October 31, 2025.

Natera, Inc. furnished a Form 8‑K announcing results for its third quarter ended September 30, 2025, and provided a related investor presentation. The press release and presentation are included as Exhibits 99.1 and 99.2. The company states the information is furnished, not "filed," under the Exchange Act and is not incorporated into other filings unless expressly stated.